BACKGROUND: For stage IV melanoma, systemic medical therapy (SMT) is used most frequently; surgery is considered an adjunct in selected patients. We retrospectively compared survival after surgery with or without SMT versus SMT alone for melanoma patients developing distant metastases while enrolled in the first Multicenter Selective Lymphadenectomy Trial. METHODS: Patients were randomized to wide excision and sentinel node biopsy, or wide excision and nodal observation. We evaluated recurrence site, therapy (selected by treating clinician), and survival after stage IV diagnosis. RESULTS: Of 291 patients with complete data for stage IV recurrence, 161 (55 %) underwentsurgery with or without SMT. Median survival was 15.8 versus 6.9 months, and 4-year survival was 20.8 versus 7.0 % for patients receiving surgery with or without SMT versus SMT alone (p < 0.0001; hazard ratio 0.406). Surgery with or without SMT conferred a survival advantage for patients with M1a (median > 60 months vs. 12.4 months; 4-year survival 69.3 % vs. 0; p = 0.0106), M1b (median 17.9 vs. 9.1 months; 4-year survival 24.1 vs. 14.3 %; p = 0.1143), and M1c (median 15.0 vs. 6.3 months; 4-year survival 10.5 vs. 4.6 %; p = 0.0001) disease. Patients with multiple metastases treated surgically had a survival advantage, and number of operations did not reduce survival in the 67 patients (42 %) who had multiple surgeries for distant melanoma. CONCLUSIONS: Our findings suggest that over half of stage IV patients are candidates for resection and exhibit improved survival over patients receiving SMT alone, regardless of site and number of metastases. We have begun a multicenter randomized phase III trial comparing surgery versus SMT as initial treatment for resectable distant melanoma.
RCT Entities:
BACKGROUND: For stage IV melanoma, systemic medical therapy (SMT) is used most frequently; surgery is considered an adjunct in selected patients. We retrospectively compared survival after surgery with or without SMT versus SMT alone for melanomapatients developing distant metastases while enrolled in the first Multicenter Selective Lymphadenectomy Trial. METHODS:Patients were randomized to wide excision and sentinel node biopsy, or wide excision and nodal observation. We evaluated recurrence site, therapy (selected by treating clinician), and survival after stage IV diagnosis. RESULTS: Of 291 patients with complete data for stage IV recurrence, 161 (55 %) underwent surgery with or without SMT. Median survival was 15.8 versus 6.9 months, and 4-year survival was 20.8 versus 7.0 % for patients receiving surgery with or without SMT versus SMT alone (p < 0.0001; hazard ratio 0.406). Surgery with or without SMT conferred a survival advantage for patients with M1a (median > 60 months vs. 12.4 months; 4-year survival 69.3 % vs. 0; p = 0.0106), M1b (median 17.9 vs. 9.1 months; 4-year survival 24.1 vs. 14.3 %; p = 0.1143), and M1c (median 15.0 vs. 6.3 months; 4-year survival 10.5 vs. 4.6 %; p = 0.0001) disease. Patients with multiple metastases treated surgically had a survival advantage, and number of operations did not reduce survival in the 67 patients (42 %) who had multiple surgeries for distant melanoma. CONCLUSIONS: Our findings suggest that over half of stage IV patients are candidates for resection and exhibit improved survival over patients receiving SMT alone, regardless of site and number of metastases. We have begun a multicenter randomized phase III trial comparing surgery versus SMT as initial treatment for resectable distant melanoma.
Authors: Kazuo Koyanagi; Steven J O'Day; Peter Boasberg; Michael B Atkins; He-Jing Wang; Rene Gonzalez; Karl Lewis; John A Thompson; Clay M Anderson; Jose Lutzky; Thomas T Amatruda; Evan Hersh; Jon Richards; Jeffrey S Weber; Dave S B Hoon Journal: Clin Cancer Res Date: 2010-04-06 Impact factor: 12.531
Authors: T F Wood; L A DiFronzo; D M Rose; P I Haigh; S L Stern; L Wanek; R Essner; D L Morton Journal: Ann Surg Oncol Date: 2001-09 Impact factor: 5.344
Authors: Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Robert Elashoff; Richard Essner; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; Edwin C Glass; He-Jing Wang Journal: N Engl J Med Date: 2006-09-28 Impact factor: 91.245
Authors: Seza A Gulec; Mark B Faries; Chris C Lee; Daniel Kirgan; C Glass; Donald L Morton; Richard Essner Journal: Clin Nucl Med Date: 2003-12 Impact factor: 7.794
Authors: Daniel E Spratt; Elizabeth A Gordon Spratt; Shenhong Wu; Antonio DeRosa; Nancy Y Lee; Mario E Lacouture; Christopher A Barker Journal: J Clin Oncol Date: 2014-08-25 Impact factor: 44.544
Authors: Mark B Faries; Anna Leung; Donald L Morton; Danielle Hari; Ji-Hey Lee; Myung-shin Sim; Anton J Bilchik Journal: J Am Coll Surg Date: 2014-05-10 Impact factor: 6.113
Authors: Peter Hersey; Hojabr Kakavand; James Wilmott; Andre van der Westhuizen; Stuart Gallagher; Kavitha Gowrishankar; Richard Scolyer Journal: Melanoma Manag Date: 2014-12-04
Authors: Allison S Dobry; Cheryl K Zogg; F Stephen Hodi; Timothy R Smith; Patrick A Ott; J Bryan Iorgulescu Journal: Cancer Immunol Immunother Date: 2018-09-06 Impact factor: 6.968
Authors: Susann-Cathrin Schüle; Thomas Kurt Eigentler; Claus Garbe; Christian la Fougère; Konstantin Nikolaou; Christina Pfannenberg Journal: Eur J Nucl Med Mol Imaging Date: 2015-09-18 Impact factor: 9.236